The study of the influence of prosteks® drug, rectal suppositories, produced by “Biopharma”, pjsc on the turpentine prostatitis in rats

Authors

  • O. M. Shapoval National University of Pharmacy, Ukraine
  • S. Yu. Shtrygol National University of Pharmacy, Ukraine
  • V. L. Karbovskiy “Biopharma”, PJSC, Ukraine
  • I. A. Shevchuk “Biopharma”, PJSC, Ukraine
  • O. V. Kurkina “Biopharma”, PJSC, Ukraine
  • T. Ye. Makovska Main Military Medical Hospital, Ukraine

DOI:

https://doi.org/10.24959/cphj.14.1310

Keywords:

chronic prostatitis, Prosteks®, prostateprotective action, turpentine prostatitis

Abstract

In this work the results of studying the influence of Prosteks® drug, rectal suppositories, produced by “Biopharma”, PJSC on the turpentine prostatitis in rats are presented. The relevance of the work is due to the fact that among the urological diseases in men older than 50 benign hyperplasia of prostate (BHP) and chronic prostatitis are the most common, and in 96.7% of patients with BPH the morphological signs of chronic prostatitis appear. A comparative evaluation of the therapeutic effect of a new drug and the reference drug “Prostatilen zinc”, rectal suppositories, concerning the influence on functional, biochemical and immunological parameters characterizing the functional state of the prostate gland has been carried out. Rectal introduction of turpentine to male rats 2 times causes severe abnormalities in the prostate condition. Treatment of male rats with Prosteks® in the dose of 168 mg/kg and Prostatilen zinc in the dose of 210 mg/kg had a strong prostateprotective action. According to its expressiveness Prosteks® drug, rectal suppositories, produced by “Biopharma”, PJSC is not inferior and even has the advantage by individual indicators over the reference drug “Prostatilen zinc”, rectal suppositories. Thus, Prosteks® drug, rectal suppositories, produced by “Biopharma”, PJSC can be considered promising for clinical trials with the purpose of further introduction into medical practice.

References

Доклінічні дослідження лікарських засобів: Метод. рекоменд. / За ред. чл.-кор. НАМН України О.В.Стефанова. – К.: Авіценна, 2001. – 528 с.

Мировая статистика здравоохранения за 2010 год. – Всемирная организация здравоохранения, 2010. – 177 с.

Сайдакова Н.О., Старцева Л.М., Кравчук Н.Г. Основні показники урологічної допомоги в Україні за 2005-06 роки: Відомче видання. – К., 2007. – 205 с.

Ткачук В.Н., Ткачук И.Н. Эффективность препарата «Витапрост форте» у больных с доброкачественной гиперплазией предстательной железы / Електронний ресурс. – Режим доступу: http://medi.ru/doc/g2401204.htm

Урология. Национальное руководство / Под ред. Н.А.Лопаткина. – М.: ГЭОТАР-Медиа, 2009. –

с.

Яковлєва Л.В., Лар’яновська Ю.Б., Міщенко О.Я. та ін. Доклінічне вивчення лікарських засобів, призначених для лікування простатитів: Метод. рекоменд. – К., 2005. – 35 с.

Drach G.W. // J. Urol. – 1998. – Vol. 120. – P. 288.

Emberton M., Andriole G., De la Rosette I. et al. // Urol. – 2003. – Vol. 61. – P. 267-273.

Kavasmaa O.T., Tyomkin D.B., Mehik A. et al. // World J. Surg. Oncol. – 2013. – №5. – Р. 211-258.

Krieger J.N. // J. Androl. – 1996. – Vol. 17. – P. 310-340.

Luo G.C., Foo K.T., Kuo T., Tan G. // Singapore Med. J. – 2013. – Vol. 54, №9. – P. 482-486.

Schroder F., Altwein I. Development of Benign Prostatic Hyperplasia. In book: Benign Prostatic Hyperplasia. A Diagnosis and Treatment Primer. – Oxford, 1992. – P. 31-50.

Wan C.D., Zhou J.B., Song Y.P. et al. // Zhonghua Nan Ke Xue. – 2013. –Vol. 19, №10. – P. 912-917.

Downloads

Published

2014-09-12

Issue

Vol. 18 No. 3 (2014)

Section

Pre-clinical studies of new drugs

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).